Scandmedical Soldk 040 Stock Debt To Equity
| K41 Stock | 0.83 0.03 3.49% |
SCANDMEDICAL SOLDK 040 fundamentals help investors to digest information that contributes to SCANDMEDICAL SOLDK-040's financial success or failures. It also enables traders to predict the movement of SCANDMEDICAL Stock. The fundamental analysis module provides a way to measure SCANDMEDICAL SOLDK-040's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SCANDMEDICAL SOLDK-040 stock.
SCANDMEDICAL |
SCANDMEDICAL SOLDK 040 Company Debt To Equity Analysis
SCANDMEDICAL SOLDK-040's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, SCANDMEDICAL SOLDK 040 has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The debt to equity for all Germany stocks is 100.0% higher than that of the company.
SCANDMEDICAL Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SCANDMEDICAL SOLDK-040's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SCANDMEDICAL SOLDK-040 could also be used in its relative valuation, which is a method of valuing SCANDMEDICAL SOLDK-040 by comparing valuation metrics of similar companies.SCANDMEDICAL SOLDK is currently under evaluation in debt to equity category among its peers.
About SCANDMEDICAL SOLDK-040 Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SCANDMEDICAL SOLDK 040's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SCANDMEDICAL SOLDK-040 using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SCANDMEDICAL SOLDK 040 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SCANDMEDICAL Stock
SCANDMEDICAL SOLDK-040 financial ratios help investors to determine whether SCANDMEDICAL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SCANDMEDICAL with respect to the benefits of owning SCANDMEDICAL SOLDK-040 security.